Warren Fingrut, MD
Hematology · Houston, TXNPI 1922615665
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. National Marrow Donor Program accounts for 81.1% of it on its own, with 15 other manufacturers making up the rest.
Across 49 payments — averaging $194.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$8K
- Astellas Pharma US Inc$452
- Incyte Corporation$321
- AbbVie$260
- Johnson & Johnson$129
- Pfizer$119
- plus $524 from 10 others
What the payments were for
- Consulting fees$3,92441%
- Travel & lodging$2,60827%
- Food & beverage$2,20323%
- Entertainment$7958%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 14 | $7,726 |
| Astellas Pharma US Inc | 8 | $452 |
| Incyte Corporation | 5 | $321 |
| AbbVie | 3 | $260 |
| Johnson & Johnson | 4 | $129 |
| Pfizer | 1 | $119 |
| Kadmon Pharmaceuticals LLC | 1 | $103 |
| Sanofi-aventis U.S. LLC | 3 | $89 |
| Merck | 2 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Jazz Pharmaceuticals Inc. | 1 | $60 |
| Sobi, Inc | 1 | $31 |
| Syndax Pharmaceuticals, Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $26 |
| Gamida Cell Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,530 in reported general payments places this provider in the 75th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 17 | $19,157 |
| Tacrolimus | 12 | $861 |
| ValacyclovirValacyclovir Hcl | 21 | $400 |
Paid to pharmacies, not to this prescriber.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Uday PopatHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.